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Abstract
Introduction: Hyperkalaemia is a common electrolyte disorder that may cause life-threatening cardiac arrythmias. We aimed to determine the 
agreement of potassium concentrations between GEM premier 3500 point-of-care blood gas analyser (POC-BGA) and Roche Cobas 6000 c501 auto-
analyser in patients with hyperkalaemia.
Methods: A prospective, cross-sectional study of all consecutive adult patients referred to the Renal Unit with a serum potassium concentration ≥ 
5.5 mmol/L was performed. A total of 59 paired venous blood samples were included in the final statistical analysis. Passing-Bablok regression and 
Bland Altman analysis were used to compare the two methods. 
Results: The median laboratory auto-analyser potassium concentration was 6.1 (5.9-7.1) mmol/L as compared to the POC-BGA potassium concen-
tration of 5.7 (5.5-6.8) mmol/L with a mean difference of - 0.43 mmol/L and 95% upper and lower limits of agreement of 0.35 mmol/L and - 1.21 
mmol/L, respectively. Regression analysis revealed proportional systematic error. Test for linearity did not indicate significant deviation (P = 0.297). 
Conclusion: Although regression analysis indicated proportional systematic error, on Bland Altman analysis, the mean difference appeared to re-
main relatively constant across the potassium range that was evaluated. Therefore, in patients presenting to the emergency department with a 
clinical suspicion of hyperkalaemia, POC-BGA potassium concentrations may be considered a surrogate for laboratory auto-analyser measurements 
once clinicians have been cautioned about this difference.
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Potassium is the most abundant cation in the hu-
man body and is predominantly confined to the 
intracellular fluid compartment (ICF) (1). Most of 
the total body potassium (98%) is located within 
the ICF compartment. This distribution of potassi-
um is the major determinant of the resting mem-
brane potential of cells required for nerve excita-
tion and muscle contraction. Potassium disorders 
may result in serious cardiac arrhythmias and/or 
muscle weakness (2). 
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Hyperkalaemia is a very common electrolyte dis-
order in hospitalised patients (3-5). The most com-
mon risk factors associated with hyperkalaemia in-
clude acute and chronic kidney disease, diabetes 
mellitus, cardiac failure, and drugs that interfere 
with the renin-angiotensin-aldosterone system 
(4,6). As the symptoms and physical findings of hy-
perkalaemia may be very subtle and nonspecific, 
the diagnosis of hyperkalaemia must be made by 
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alternative means. Since hyperkalaemia affects 
cardiac conduction, the electrocardiogram (ECG) is 
frequently used to identify patients at imminent 
risk for arrhythmias. This investigation is non-inva-
sive, readily available, and easily performed in the 
emergency department. Numerous studies have 
reported that the ECG has poor diagnostic accura-
cy, regardless of the degree of hyperkalaemia (7,8). 
Therefore, direct measurements are required to 
accurately determine blood potassium concentra-
tion. 
Two types of blood tests are possible. Serum or 
plasma potassium concentration can be measured 
in the laboratory, or whole blood potassium con-
centration can be determined by point-of-care 
blood gas analysers (POC-BGA). There may be a 
delay in the processing of the laboratory samples 
which may cause a factitious increased potassium 
concentration as well as delaying the initiation of 
therapy and therefore POC-BGA is an attractive al-
ternative. It has been recommended that the po-
tassium concentrations on POC-BGA can be relia-
bly used in the emergency department (9). 
Prompt access to results is crucial in the manage-
ment of patients with life-threatening but reversi-
ble medical conditions such as hyperkalaemia. The 
reliance on point-of-care devices for clinical deci-
sion-making, particularly in the emergency set-
ting, has gained much popularity due to its ease of 
use, less reliance on technical staff members, and 
most importantly, a marked reduction in turna-
round time (TAT) (10,11). 
Pseudohyperkalaemia is defined as a difference 
between serum and plasma potassium concentra-
tion of greater than 0.3 to 0.4 mmol/L provided 
that the sample was collected using the correct 
phlebotomy technique, remained at room tem-
perature, and was analysed within one hour of 
sample collection. It is frequently encountered 
during thrombocytosis due to potassium release 
from platelets during clotting (12). Other causes in-
clude haemolysis, leukocytosis, pre-analytical er-
rors such as potassium-ethylenediaminetetraacet-
ic acid (K-EDTA) contamination, and other incor-
rect phlebotomy techniques such as fist clenching, 
prolonged tourniquet application, as well as de-
lays in sample transport to the laboratory (13). 
Few relevant studies have reported on the diag-
nostic accuracy of POC-BGA potassium concentra-
tion measurements relative to laboratory meas-
urements, however, the average potassium con-
centrations reported in these studies were not in 
the hyperkalaemic range (14-17). We could only 
identify two retrospective studies that were per-
formed in patients with hyperkalaemia (9,18). In 
view of the conflicting results from previous retro-
spective studies, we performed a prospective 
cross-sectional study of patients with hyperkalae-
mia with the aim to determine the agreement be-
tween GEM Premier 3500 (Instrumentation Labo-
ratory, Massachusetts, United States of America) 
POC-BGA and Roche Cobas 6000 c501 (Roche Di-




A cross-sectional study was conducted at Tyger-
berg Hospital, a 1380 bed tertiary care teaching 
hospital affiliated to the Faculty of Medicine and 
Health Sciences of Stellenbosch University. Adult 
patients (age > 18 years) referred to the Renal Unit 
with acute kidney injury or chronic kidney disease 
with hyperkalaemia (≥ 5.5 mmol/L) were included. 
To reduce the effect of pseudohyperkalaemia, all 
participants with leukocyte counts > 100 x109/L, 
platelet counts > 500 x109/L, and haemolysis were 
excluded, as shown in Figure 1. 
Informed consent was obtained. Patients were re-
ferred based on prior laboratory auto-analyser 
measurements. This study was approved by the 
Human Research Ethics Committee of Stellenbos-
ch University (study number: 7082) and performed 
according to the Declaration of Helsinki.
Methods
Paired venous blood samples were obtained from 
participants over a 6-week period from October to 
November 2018. Phlebotomy was performed by 
the same individual using the Joint European Fed-
eration of Clinical Chemistry and Laboratory Medi-
https://doi.org/10.11613/BM.2020.030702 Biochem Med (Zagreb) 2020;30(3):030702 
  3
Mogamat-Yazied C. et al. Point-of-care testing in patients with hyperkalaemia
cine (EFLM) and the Latin America Confederation 
of Clinical Biochemistry (COLABIOCLI) recommen-
dations for venous blood sampling (19). Paired ve-
nous blood samples were drawn simultaneously 
from the brachial vein and a vein on the dorsum of 
the hand of the same upper limb because the con-
tralateral upper limb was frequently cannulated 
with the infusion of intravenous fluids. 
For the POC-BGA sample, 2.5 mL of venous blood 
was drawn with a 23-gauge, 0.65 mm butterfly 
needle into a prefilled, spray-dried calcium-bal-
anced heparin syringe BD A-line syringe (Becton 
Dickinson, Wokingham, United Kingdom), capped 
and turned around gently for one mixing cycle. 
POC-BGA was performed within five minutes us-
ing the GEM Premier 3500 system (Instrumenta-
tion Laboratory, Massachusetts, United States of 
America). 
For the laboratory analysis, a sample of 2.5 mL of 
venous blood was obtained using a closed-loop-
system with the help of a vacutainer and bulldog 
needle into a serum separation tube (BD Vacutain-
er, Becton Dickinson, Wokingham, United King-
dom). The sample was mixed in the tube by gently 
inverting the tube for one mixing cycle. The sam-
ples were made to stand for at least 30 minutes at 
room temperature to allow it to clot and thereafter 
it was centrifuged for 10 minutes at a speed of 
3000 revolutions per minute. The time of sample 
collection and time to centrifugation was noted. 
Samples were hand delivered to a designated lab-
oratory technologist at the chemical pathology 
laboratory immediately following centrifugation. 
The GEM Premier 3500 system (Instrumentation 
Laboratory, Massachusetts, United States of Amer-
ica) determines the potassium concentration us-
ing a potentiometric direct ion selective electrode 
(ISE). It does not subscribe to an external quality 
assurance (EQA) program, instead it uses Intelli-
gent Quality Management (iQM). This internal 
quality assurance system provides continuous 
monitoring of the analytical process with real-
time, automatic error detection. A specific am-
poule calibrates the machine for high potassium 
concentrations (range: 6.2-6.8 mmol/L). During the 
study period, the measured analytical imprecision 
was 1% at a nominal target value of 6.8 mmol/L. 
In the laboratory, the potassium concentration 
and the haemolysis index were measured using 
the Roche Cobas 6000 c501 system (Roche Diag-
nostics GmbH, Mannheim, Germany). Serum po-
tassium concentration is measured using an indi-
rect ISE method. For a potassium concentration of 
6.44 mmol/L, the within-assay coefficient of varia-
tion (CV) was 0.5% and the within-laboratory CV 
was 0.7%. These were within the manufacturer’s 
recommendation of 0.6% and 0.7%, respectively. 
Leukocyte and platelet counts were measured us-
ing the Siemens ADVIA 2120i haematology system 
(Siemens Healthcare GmbH, Erlangen, Germany). 
The total allowable error (TEa) used for serum po-
tassium was 5.6%, as specified in the Westgard Bi-
ological Variation Database (20).
Statistical analysis
Data were analysed using StataCorp. 2019. Stata 
Statistical Software: Release 16. College Station, 
TX: StataCorp LLC. The Shapiro-Wilks test was 
used to test for data normality. Data were ex-
pressed as median and interquartile range. Bland 
Altman analysis and Passing Bablok regression 
were used to assess the agreement between the 
two measurement methods. The 95% upper and 
A total of 76 participants
were recruited
Two simultaneous venous
blood samples were drawn
59 participants were used in
final data analysis
17 participants were excluded from
data analysis:
•  Laboratory serum potassium
   concentration < 5.5 mmol/L (N = 13)
•  Thrombocytosis (N = 3)
•  Missing data (N = 1)
Figure 1. Consort diagram
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lower limits of agreement and mean difference 
was reported for the Bland Altman analysis and 
the 95% confidence interval (95%CI) for the inter-
cept and the slope were reported for the Passing 
Bablok regression line. The cumulative sum test 
(cusum test) was used to calculate linearity be-
tween the two methods. 
Results
Seventy-six patients were referred with hyper-
kalaemia of which 59 were included in the final 
statistical analysis. Seventeen patients were ex-
cluded from the final statistical analysis because 
the laboratory potassium concentration was < 5.5 
mmol/L (N = 13), had thrombocytosis (N = 3), and 
missing data (N = 1).
The median age was 40 (32-47) years. Thirty par-
ticipants were female. All participants had kidney 
disease with 38 having acute kidney injury and 21 
with chronic kidney disease.
The median time from sample collection to com-
pletion of centrifugation of laboratory samples 
was 33 (30-36) minutes. The median laboratory 
potassium concentration was 6.1 (5.9-7.1) mmol/L 
as compared to the POC-BGA potassium concen-
tration of 5.7 (5.5-6.8) mmol/L with a mean differ-
ence of -0.4 mmol/L. 
Figure 2 shows the Passing Bablok regression line 
with associated 95%CI for the intercept and the 
slope. The mean difference was - 0.43 mmol/L. The 
Bland Altman analysis shows the mean difference 
with the associated 95% upper and lower limits of 
agreement for the two methods (Figure 3). 
Discussion
To the best of our knowledge, this was the first 
prospective study to determine the agreement 
between POC-BGA and laboratory auto-analyser 
potassium concentrations in patients with hyper-
kalaemia and kidney disease. A difference in meas-
urements was identified between GEM Premier 
3500 POC-BGA and Roche Cobas 6000 c501 auto-
analyser and most of the potassium values for the 
POC-BGA were outside of the TEa of 5.6%. With 
Figure 2. Passing Bablok regression of the two methods for 
hyperkalaemia. Scatter diagram with regression line and con-
fidence intervals for regression line. Cusum test for linearity did 
not indicate significant deviation (P = 0.297). Gray lines repre-
sent 95% confidence intervals, black line represents the re-
gression line (equation: y = 0.59 + 0.846x, 95%CI for the inter-
cept was -0.09 to 1.26 and for the slope the 95% CI was 0.74 to 
0.96) and dotted line represents the line of equality. POC-BGA 
– point-of-care blood gas analyser. [K] – potassium concentra-
tion.
Figure 3. The Bland Altman analysis. Dashed lines indicate up-
per and lower limits of agreement and solid line indicates the 
mean difference. [K] – potassium concentration. POC-BGA – 
point-of-care blood gas analyser. SD – standard deviation.
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the visual inspection of the Bland Altman analysis, 
the mean difference remained relatively constant 
across the full range of potassium concentrations. 
However, Passing Bablok regression analysis did 
not support a constant systematic error between 
the two methods since the 95%CI for the intercept 
did not differ significantly from 0; however, the 
95%CI for the slope differed significantly from 1, 
indicating the presence of proportional systematic 
error (21). Although regression analysis indicated 
proportional error as the potassium concentration 
rose, we limited our samples to only include potas-
sium concentrations of more than or equal to 5.5 
mmol/L. This may have been diminished or absent 
if the full range of potassium concentrations were 
evaluated. Previous studies that included samples 
across a wider range of potassium concentrations 
did not report any proportional systematic error 
(22-24). 
Few studies have reported on the agreement be-
tween the two methods. A study that examined 
the agreement between the two methods in pa-
tients with chronic kidney disease, reported a dif-
ference of -0.4 mmol/L (16). Although the latter 
study had a larger sample size, the median potas-
sium concentrations were < 5.0 mmol/L. Despite 
this, the reported total error was within the recom-
mended TEa at a threshold value of 5.5 mmol/L. 
Another study that compared the agreement of 
numerous analytes, including potassium concen-
tration in critically ill patients, reported a differ-
ence of only 0.20 mmol/L, with most of the potas-
sium values within the normal range. Gupta et al. 
compared 112 paired arterial blood gas samples 
with serum laboratory samples and reported a dif-
ference for potassium concentration of -0.14 
mmol/L (25). The mean serum potassium concen-
tration was within the normal range. In the latter 
study, after grouping serum potassium concentra-
tions into < 3.5 mmol/L, 3.5 to 5.2 mmol/L and > 
5.2 mmol/L, the associated differences were 0.07 
mmol/L, 0.26 mmol/L and 0.28 mmol/L, respec-
tively. The only other study to exclusively examine 
the agreement between the two methods with se-
rum potassium concentrations of more than or 
equal to 6.0 mmol/L, reported a high mean differ-
ence of 0.62 mmol/L (18). Therefore, the difference 
between the two methods appears to be reduced 
when the whole or normal range of potassium 
concentrations is evaluated. However, the differ-
ence between the two methods increases only 
when evaluating the higher range of potassium 
concentrations, as was found in this study and by 
others (18).
The type of blood sample required for analysis 
may play a role. While POC-BGA requires a whole 
blood sample, laboratory auto-analysers require a 
serum sample. To utilise whole blood for POC-
BGA, a heparinised sample is required. A study 
that evaluated the effects of different concentra-
tions of liquid heparin and heparin vacutainers on 
the measurement of electrolytes reported that liq-
uid formulations had a significant negative bias on 
measured concentrations of electrolytes (26). On 
the other hand, serum samples may be suscepti-
ble to pseudohyperkalaemia. Two factors that con-
tribute to this are the absolute potassium concen-
trations and the number of platelets (27). In serum, 
during the clotting process, potassium released by 
platelets cause the serum potassium concentra-
tion to rise and can cause a difference between 
the two methods of approximately 0.3 mmol/L, 
even when platelet counts are within the normal 
range (28). Drogies et al. reported that the differ-
ence between the measured plasma and serum 
potassium concentrations were < 0.1 mmol/L in 
the presence of hypokalaemia, while it was > 0.5 
mmol/L during hyperkalaemia (27). Therefore, an 
additional factor contributing to the difference in 
measurements identified in our study may be the 
inclusion of samples with only high potassium 
concentrations.  
This study was the first to prospectively determine 
the agreement between POC-BGA and laboratory 
auto-analyser potassium concentrations in pa-
tients with hyperkalaemia. As this study was con-
ducted using a standardised phlebotomy tech-
nique, hand-delivery of samples to the laboratory 
and the exclusion of patients with thrombocytosis, 
and hyperleukocytosis, the difference may be 
greater in less ideal clinical settings. Also, our re-
sults may not be generalisable since the analytic 
imprecision may differ between laboratories.
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In conclusion, the POC-BGA is not a replacement 
for laboratory auto-analyser measurements but 
should rather be viewed as complementary, allow-
ing for a rapid response in the emergency depart-
ment. Although regression analysis indicated a 
proportional systematic error, on Bland Altman 
analysis, the mean difference appeared to remain 
relatively constant across the potassium range 
that was evaluated. Therefore, in patients present-
ing to the emergency department with a clinical 
suspicion of hyperkalaemia, POC-BGA potassium 
concentrations may be considered a surrogate for 
laboratory auto-analyser measurements once cli-
nicians have been cautioned about this difference.
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